Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated July 13, 2023, titled "FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility".
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated July 13, 2023, titled "FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility".